Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products. Its only currently marketed product is ARCALYST® (rilonacept) for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). The company maintains significant strategic collaborations with sanofi-aventis (aflibercept and antibody discovery) and Bayer HealthCare (VEGF Trap-Eye).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Total Revenues | $65,584 | $182,620 |
| Net Loss | $(21,115) | $(51,192) |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.65) |
| Research & Development Expenses | $73,855 | $201,702 |
| Cash and Cash Equivalents | $314,684 | (Balance Sheet Item) |
| Marketable Securities | $376,527 | (Balance Sheet Item) |
| Notes Payable (Current) | $117,503 | (Balance Sheet Item) |
Note: The company reported a cumulative loss of $844.4 million from inception through September 30, 2008.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly from $22.3 million in Q3 2007 to $65.6 million in Q3 2008. This was driven primarily by increased contract research and development revenue from sanofi-aventis ($42.0 million vs. $9.2 million) and Bayer HealthCare ($9.0 million vs. $0), alongside the introduction of net product sales for ARCALYST ($2.7 million).
- Expense Increases: Operating expenses rose to $85.5 million in Q3 2008 from $61.0 million in Q3 2007. Research and development expenses increased by $22.1 million, attributed to higher payroll, clinical trial costs, and manufacturing costs for VEGF Trap-Eye and monoclonal antibodies.
- Net Loss Improvement: Despite higher expenses, the net loss narrowed to $21.1 million in Q3 2008 from $35.8 million in Q3 2007, primarily due to the substantial revenue growth from collaborations.
- Debt Reduction: The company repurchased $82.5 million in principal amount of its 5.5% Convertible Senior Subordinated Notes during the first nine months of 2008. The remaining $117.5 million outstanding at period-end was repaid in full upon maturity in October 2008.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- ARCALYST: Phase 3 studies for gout flare prevention and acute gout are planned for the first half of 2009. Commercial shipments for CAPS are projected to total approximately $10 million in 2008.
- VEGF Trap-Eye: Phase 3 trials (VIEW 1 and VIEW 2) for wet AMD are ongoing. A Phase 2 study in diabetic macular edema is planned for early 2009.
- Aflibercept: Four Phase 3 trials in oncology (colorectal, pancreatic, prostate, and lung cancer) are enrolling patients.
- Antibodies: The company plans to file an IND for a Dll4 antibody by the end of 2008 and advance an average of two to three antibody candidates into clinical development annually.
- Liquidity: Management believes existing capital resources, including collaboration funding, will meet operating needs through at least 2012. However, the company expects to incur substantial losses over the next several years.
- Investment Risks: The company recorded $2.3 million in other-than-temporary impairment charges on marketable securities during the first nine months of 2008 due to credit quality deterioration. Management warns that further declines in market value could result in additional material charges.
- Legal & IP: The company resolved a dispute with Cellectis via a $12.5 million payment and amended license agreement. Risks remain regarding potential patent infringement claims from third parties (e.g., Genentech, Roche) and the uncertainty of regulatory approvals.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of revenue from sanofi-aventis and Bayer HealthCare, which comprised the vast majority of total revenue ($149.9 million of $182.6 million for the nine months ended Sep 30, 2008).
- Debt Status: Confirm the full repayment of the $117.5 million convertible notes in October 2008 and the absence of new debt obligations.
- Investment Portfolio: Monitor the fair value of the $376.5 million marketable securities portfolio for further impairment charges given the volatile economic environment.
- ARCALYST Commercialization: Assess whether the projected $10 million in 2008 shipments for ARCALYST will materialize and if the product can achieve profitability given the small patient population for CAPS.
- Clinical Milestones: Track the enrollment and results of the Phase 3 trials for VEGF Trap-Eye and aflibercept, as these are critical for future revenue potential.